(also known as Mitoglitazone) is an investigational drug originally developed to treat Type 2 diabetes. It is currently being explored for its potential to treat neurodegenerative diseases like Parkinson’s and Alzheimer’s.
: Phase 2a trials suggested it may help maintain glucose metabolism in brain regions associated with cognitive decline. Availability and Purchase Information
In clinical trials, MSDC-0160 has been reported as generally well-tolerated.
: Shown to reduce neuroinflammation and protect dopamine-producing neurons in animal models.
Note: Prices are based on MedChemExpress data and are subject to change.
: Successfully completed Phase 2b trials where it lowered HbA1c levels similarly to pioglitazone (Actos) but with 50% less fluid retention.